{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:42:41Z","timestamp":1794508961099,"version":"4.9.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T00:00:00Z","timestamp":1612569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI131983"],"award-info":[{"award-number":["R01AI131983"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["R21AT011088"],"award-info":[{"award-number":["R21AT011088"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Liver Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.livres.2021.02.001","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T16:37:01Z","timestamp":1613061421000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Clinical perspectives of isoniazid-induced liver injury"],"prefix":"10.1016","volume":"5","author":[{"given":"Saifei","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.livres.2021.02.001_bib1","author":"World Health Organization"},{"key":"10.1016\/j.livres.2021.02.001_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.micro.61.111606.122346","article-title":"The mechanism of isoniazid killing: clarity through the scope of genetics","volume":"61","author":"Vilch\u00e8ze","year":"2007","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.livres.2021.02.001_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3122\/jabfm.2014.05.140062","article-title":"Advances in diagnosis and treatment of latent tuberculosis infection","volume":"27","author":"Chapman","year":"2014","journal-title":"J\u00a0Am Board Fam Med"},{"key":"10.1016\/j.livres.2021.02.001_bib4","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.livres.2021.02.001_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","article-title":"Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis","volume":"84","author":"Mitchell","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.livres.2021.02.001_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0016-5085(19)32568-5","article-title":"Isoniazid-associated hepatitis in 114 patients","volume":"69","author":"Black","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2021.02.001_bib7","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1378\/chest.128.1.116","article-title":"Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic","volume":"128","author":"Fountain","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.livres.2021.02.001_bib9","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1086\/381446","article-title":"Drug-induced liver injury","volume":"38","author":"Kaplowitz","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib10","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union against Tuberculosis Committee on Prophylaxis","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.livres.2021.02.001_bib11","first-page":"486","article-title":"Isoniazid-related fatal hepatitis","volume":"164","author":"Millard","year":"1996","journal-title":"West J Med"},{"key":"10.1016\/j.livres.2021.02.001_bib12","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]","year":"2012"},{"key":"10.1016\/j.livres.2021.02.001_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1164\/arrd.1972.106.3.357","article-title":"Isoniazid-associated hepatitis. Report of an outbreak","volume":"106","author":"Garibaldi","year":"1972","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1164\/ajrccm\/146.6.1643a","article-title":"Isoniazid-associated hepatitis deaths: a review of available information","volume":"146","author":"Moulding","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib15","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.7326\/0003-4819-71-6-1113","article-title":"Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid","volume":"71","author":"Scharer","year":"1969","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.livres.2021.02.001_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.livres.2021.02.001_bib17","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.cgh.2015.02.024","article-title":"Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity","volume":"13","author":"Hayashi","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin. A meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.livres.2021.02.001_bib19","first-page":"560","article-title":"Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis","volume":"159","author":"Salpeter","year":"1993","journal-title":"West J Med"},{"key":"10.1016\/j.livres.2021.02.001_bib20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494","article-title":"Isoniazid-associated hepatitis deaths: a review of available information","volume":"145","author":"Snider","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00004836-199404000-00013","article-title":"Drug disposition and hepatotoxicity in the elderly","volume":"18","author":"Schenker","year":"1994","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.livres.2021.02.001_bib22","first-page":"1499","article-title":"The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity","volume":"8","author":"Fern\u00e1ndez-Villar","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.livres.2021.02.001_bib24","first-page":"501","article-title":"Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002","volume":"9","author":"LoBue","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.livres.2021.02.001_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0736-4679(97)00242-4","article-title":"Isoniazid poisonings in New York City","volume":"16","author":"Sullivan","year":"1998","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.livres.2021.02.001_bib27","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1073\/pnas.95.21.12208","article-title":"Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction","volume":"95","author":"Bertilsson","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.livres.2021.02.001_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0092-8674(00)80900-9","article-title":"An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway","volume":"92","author":"Kliewer","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.livres.2021.02.001_bib29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2021.02.001_bib30","first-page":"1072","article-title":"Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin","volume":"133","author":"Sarma","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib31","first-page":"603","article-title":"Acute liver failure caused by isoniazid in a child receiving carbamazepine","volume":"2","author":"Berkowitz","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0034-1375956","article-title":"Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs","volume":"34","author":"Devarbhavi","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/345906","article-title":"Isoniazid hepatotoxicity among drug users: the role of hepatitis C","volume":"36","author":"Fern\u00e1ndez-Villar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib34","doi-asserted-by":"crossref","first-page":"107465","DOI":"10.1016\/j.drugalcdep.2019.04.036","article-title":"Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia","volume":"204","author":"Mukherjee","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.livres.2021.02.001_bib35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1191\/096032700674230830","article-title":"Isoniazid- and rifampicin-induced oxidative hepatic injury--protection by N-acetylcysteine","volume":"19","author":"Attri","year":"2000","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.livres.2021.02.001_bib37","first-page":"1978","article-title":"Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients","volume":"90","author":"Ozick","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.livres.2021.02.001_bib38","first-page":"78","article-title":"Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment","volume":"11","author":"Pukenyte","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.phrs.2004.10.009","article-title":"Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis treatment","volume":"51","author":"Sharifzadeh","year":"2005","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.livres.2021.02.001_bib40","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1183\/09031936.96.09102026","article-title":"Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis","volume":"9","author":"Schaberg","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.livres.2021.02.001_bib41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0168-8278(99)80325-0","article-title":"Antecedent liver disease and drug toxicity","volume":"31","author":"Schenker","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.taap.2008.01.002","article-title":"Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model","volume":"229","author":"Tafazoli","year":"2008","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.livres.2021.02.001_bib43","article-title":"Hepatotoxicity induced by isoniazid-lipopolysaccharide through endoplasmic reticulum stress, autophagy, and apoptosis pathways in zebrafish","volume":"63","author":"Zhang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.livres.2021.02.001_bib44","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/1547691X.2013.860644","article-title":"Isoniazid-induced liver injury and immune response in mice","volume":"11","author":"Metushi","year":"2014","journal-title":"J\u00a0Immunotoxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib45","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2217\/pgs.09.66","article-title":"Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population","volume":"10","author":"Yamada","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.livres.2021.02.001_bib46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1476-5381.2009.00173.x","article-title":"Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes?","volume":"157","author":"Yue","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.livres.2021.02.001_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jmg.6.4.405","article-title":"An improved and simplified method of detecting the acetylator phenotype","volume":"6","author":"Evans","year":"1969","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.livres.2021.02.001_bib48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1172\/JCI114527","article-title":"Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver","volume":"85","author":"Grant","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2021.02.001_bib49","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2217\/14622416.9.11.1673","article-title":"Update on the pharmacogenetics of NATs: structural considerations","volume":"9","author":"Stanley","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.livres.2021.02.001_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2021.02.001_bib51","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5588\/ijtld.11.0377","article-title":"NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis","volume":"16","author":"Wang","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib52","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180845","article-title":"Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence","volume":"39","author":"Khan","year":"2019","journal-title":"Biosci Rep"},{"key":"10.1016\/j.livres.2021.02.001_bib53","first-page":"3177","article-title":"N-acetyl transferase 2 polymorphisms associated with isoniazid pharmacodynamics: molecular features for ligand interaction","volume":"30","author":"Ohkura","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.livres.2021.02.001_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev.pharmtox.44.101802.121704","article-title":"Oxidative stress, toxicology, and pharmacology of CYP2E1","volume":"44","author":"Caro","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib55","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","article-title":"Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis","volume":"26","author":"Bose","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib56","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"Huang","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2021.02.001_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","article-title":"CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis","volume":"62","author":"Vuilleumier","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.livres.2021.02.001_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jgh.12069","article-title":"Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs","volume":"28","author":"Chamorro","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085905","article-title":"The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1","volume":"9","author":"Xiang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2021.02.001_bib60","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/hep.22370","article-title":"Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury","volume":"48","author":"Lucena","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2021.02.001_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5588\/ijtld.12.0447","article-title":"GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis","volume":"17","author":"Tang","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib62","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1440-1746.2001.02585.x","article-title":"Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 \u2018null\u2019 mutation","volume":"16","author":"Roy","year":"2001","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2007.02.009","article-title":"Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury","volume":"47","author":"Huang","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib64","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/tpj.2010.5","article-title":"Genetic variation in carboxylesterase genes and susceptibility to isoniazid-induced hepatotoxicity","volume":"10","author":"Yamada","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.livres.2021.02.001_bib65","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1478-3231.2011.02697.x","article-title":"TNF-\u03b1 genetic polymorphism -308G\/A and antituberculosis drug-induced hepatitis","volume":"32","author":"Kim","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.livres.2021.02.001_bib66","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.livres.2021.02.001_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tube.2011.12.004","article-title":"Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients","volume":"92","author":"Nanashima","year":"2012","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.livres.2021.02.001_bib68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40261-017-0572-6","article-title":"Genetic polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to anti-tuberculosis drug-induced hepatotoxicity: a Chinese population-based prospective case-control study","volume":"37","author":"Sun","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.livres.2021.02.001_bib69","doi-asserted-by":"crossref","first-page":"376","DOI":"10.5588\/ijtld.11.0404","article-title":"UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications","volume":"16","author":"Chang","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.livres.2021.02.001_bib70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3109\/03602532.2014.984070","article-title":"Pharmacogenetics of isoniazid-induced hepatotoxicity","volume":"47","author":"Perwitasari","year":"2015","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.livres.2021.02.001_bib71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01086149","article-title":"Pharmacokinetics of isoniazid metabolism in man","volume":"4","author":"Ellard","year":"1976","journal-title":"J\u00a0Pharmacokinet Biopharm"},{"key":"10.1016\/j.livres.2021.02.001_bib72","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1021\/tx200168d","article-title":"Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States","volume":"24","author":"Stepan","year":"2011","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1021\/tx500285k","article-title":"Auto-oxidation of isoniazid leads to isonicotinic-lysine adducts on human serum albumin","volume":"28","author":"Meng","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib74","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1021\/tx300341r","article-title":"Direct oxidation and covalent binding of isoniazid to rodent liver and human hepatic microsomes: humans are more like mice than rats","volume":"25","author":"Metushi","year":"2012","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib75","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/15287398209530308","article-title":"Studies on hydrazine hepatotoxicity. 1. Pathological findings","volume":"10","author":"Scales","year":"1982","journal-title":"J\u00a0Toxicol Environ Health"},{"key":"10.1016\/j.livres.2021.02.001_bib76","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/15287398209530309","article-title":"Studies on hydrazine hepatotoxicity. 2. Biochemical findings","volume":"10","author":"Timbrell","year":"1982","journal-title":"J\u00a0Toxicol Environ Health"},{"key":"10.1016\/j.livres.2021.02.001_bib77","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cpt197518170","article-title":"Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites","volume":"18","author":"Mitchell","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.livres.2021.02.001_bib78","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/hep.26564","article-title":"Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure","volume":"59","author":"Metushi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2021.02.001_bib79","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1021\/acs.chemrestox.6b00098","article-title":"Protein targets of isoniazid-reactive metabolites in mouse liver in\u00a0vivo","volume":"29","author":"Koen","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib80","first-page":"803","article-title":"Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients","volume":"25","author":"Sotsuka","year":"2011","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.livres.2021.02.001_bib81","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.taap.2012.10.024","article-title":"CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid","volume":"266","author":"Cheng","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.livres.2021.02.001_bib82","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/toxsci\/kfh232","article-title":"Hepatic gene expression and lipid homeostasis in C57BL\/6 mice exposed to hydrazine or acetylhydrazine","volume":"82","author":"Richards","year":"2004","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.livres.2021.02.001_bib83","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1021\/acs.chemrestox.6b00121","article-title":"Chronic treatment with isoniazid causes protoporphyrin IX accumulation in mouse liver","volume":"29","author":"Sachar","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib84","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/jpet.115.228130","article-title":"Protoporphyrin IX: the good, the bad, and the ugly","volume":"356","author":"Sachar","year":"2016","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.livres.2021.02.001_bib85","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1042\/cs0770473","article-title":"Protoporphyrin IX-induced impairment of biliary lipid secretion in the rat","volume":"77","author":"Perez-Barriocanal","year":"1989","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.livres.2021.02.001_bib86","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1053\/j.gastro.2011.06.078","article-title":"Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model","volume":"141","author":"Lyoumi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2021.02.001_bib87","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/toxsci\/kfy294","article-title":"The isoniazid metabolites hydrazine and pyridoxal isonicotinoyl hydrazone modulate heme biosynthesis","volume":"168","author":"Brewer","year":"2019","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.livres.2021.02.001_bib88","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nm.3104","article-title":"Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy","volume":"19","author":"Li","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2021.02.001_bib89","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2133\/dmpk.DMPK-11-RG-055","article-title":"Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine","volume":"26","author":"Li","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.livres.2021.02.001_bib90","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1124\/dmd.116.070920","article-title":"A\u00a0high dose of isoniazid disturbs endobiotic homeostasis in mouse liver","volume":"44","author":"Li","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.livres.2021.02.001_bib91","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/0006-3002(54)90203-6","article-title":"Identification of isonicotinoylhydrazones of pyruvic and alpha-ketoglutaric acid in rat urine after treatment with isonicotinic acid hydrazide (isoniazid)","volume":"14","author":"Zamboni","year":"1954","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.livres.2021.02.001_bib92","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1651-2227.2010.01696.x","article-title":"Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid","volume":"99","author":"Cilliers","year":"2010","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.livres.2021.02.001_bib93","first-page":"45","article-title":"Effect of isoniazid on the loss of pyridoxal phosphate from, and its distribution in, the body of the rat","volume":"88","author":"Sevigny","year":"1966","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.livres.2021.02.001_bib94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0021-9258(18)65474-2","article-title":"The isolation and properties of the isonicotinic acid hydrazide analogue of diphosphopyridine nucleotide","volume":"209","author":"Zatman","year":"1954","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2021.02.001_bib95","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.livres.2021.02.001_bib96","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2012.12.001","article-title":"Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management","volume":"3","author":"Ramappa","year":"2013","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib97","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2021.02.001_bib98","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.phrs.2008.10.006","article-title":"Effects of rifampin on CYP2E1-dependent hepatotoxicity of isoniazid in rats","volume":"59","author":"Yue","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.livres.2021.02.001_bib99","doi-asserted-by":"crossref","first-page":"13258","DOI":"10.4238\/2015.October.26.22","article-title":"MicroRNA-122 is involved in oxidative stress in isoniazid-induced liver injury in mice","volume":"14","author":"Song","year":"2015","journal-title":"Genet Mol Res"},{"key":"10.1016\/j.livres.2021.02.001_bib100","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/liv.12958","article-title":"Chronic liver injury induced by drugs: a systematic review","volume":"35","author":"Stine","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.livres.2021.02.001_bib101","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nbt.2838","article-title":"Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing","volume":"32","author":"Shuhendler","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.livres.2021.02.001_bib102","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.freeradbiomed.2013.07.038","article-title":"Isoniazid-induced cell death is precipitated by underlying mitochondrial complex I dysfunction in mouse hepatocytes","volume":"65","author":"Lee","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.livres.2021.02.001_bib103","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.taap.2006.12.013","article-title":"Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?","volume":"220","author":"Boelsterli","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.livres.2021.02.001_bib104","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/01480545.2015.1092039","article-title":"Mitochondrial oxidative stress and dysfunction induced by isoniazid: study on isolated rat liver and brain mitochondria","volume":"39","author":"Ahadpour","year":"2016","journal-title":"Drug Chem Toxicol"},{"key":"10.1016\/j.livres.2021.02.001_bib105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/toxsci\/kfu094","article-title":"A\u00a0systems biology approach utilizing a mouse diversity panel identifies genetic differences influencing isoniazid-induced microvesicular steatosis","volume":"140","author":"Church","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.livres.2021.02.001_bib106","first-page":"97","article-title":"Evaluation of isoniazid-associated hepatitis by immunological tests","volume":"32","author":"Warrington","year":"1978","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.livres.2021.02.001_bib107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2222.1982.tb02521.x","article-title":"The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis","volume":"12","author":"Warrington","year":"1982","journal-title":"Clin Allergy"}],"container-title":["Liver Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568421000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568421000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:46:04Z","timestamp":1762872364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542568421000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2542568421000040"],"URL":"https:\/\/doi.org\/10.1016\/j.livres.2021.02.001","relation":{},"ISSN":["2542-5684"],"issn-type":[{"value":"2542-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspectives of isoniazid-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Liver Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.livres.2021.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Third Affiliated Hospital of Sun Yat-sen University. Publishing Services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}